IN BRIEF: Tissue Regenix reports narrowed loss and higher revenue
21st Mar 2023 12:37
Tissue Regenix Group PLC - Leeds, England-based medical device company - Reports revenue of USD24.5 million for 2022, up 24% from USD19.7 million a year earlier. Particularly, BioRinse increased by 26% to USD16.0 million from USD12.7 million. Pretax loss narrows to USD2.8 million from USD5.1 million in 2021, as operating loss narrows to USD2.0 million from USD4.4 million. Declares no dividend for the year, unchanged from a year prior. Looking ahead, Tissue Regenix says it is well prepared for additional market fluctuations as markets continue to normalise post-pandemic. Read More